Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of August 2024, with a report date of August 14, 2024. The filing serves to disseminate a press release regarding clinical study results for the Company's ProSense® cryoablation system.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical developments rather than financial performance.
Material Changes
The primary material event reported is the announcement of an independent study demonstrating that Icecure's ProSense® system destroyed 100% of breast cancer tumors in patients who elected cryoablation over surgery. No financial changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
The press release incorporates "Forward Looking Statements" by reference into the Company's Registration Statements on Form F-3 and Form S-8. The filing does not contain specific numerical guidance or detailed risk factors within the text provided, other than the standard incorporation of forward-looking language.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed study methodology and patient demographics.
- Review the incorporated "Forward Looking Statements" in the referenced Form F-3 and Form S-8 registration statements for specific risk disclosures.
- Confirm the regulatory status of the ProSense® system in relevant markets following these study results.
- Check subsequent filings for any financial impact or commercialization plans resulting from this clinical data.